Intervention

AZD6234

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 9 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials9
Recruiting3
Common conditions7
Lead sponsors shown1
Advertisement

Clinical trials

9 shown
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightNCT07784270 · 2026-08-20
RECRUITING
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusNCT07784725 · 2026-08-19
RECRUITING
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or ObesityNCT07013643 · 2025-06-04
RECRUITING
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightNCT07017179 · 2025-05-20
ACTIVE_NOT_RECRUITING
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor AgonistNCT06851858 · 2025-03-12
COMPLETED
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneNCT06862791 · 2025-02-18
COMPLETED
A Study in Participants With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06595238 · 2024-10-01
COMPLETED
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or ObeseNCT06132841 · 2023-11-13
COMPLETED
Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or ObeseNCT05511025 · 2022-09-20
COMPLETED

Trial status mix

COMPLETED5
RECRUITING3
ACTIVE_NOT_RECRUITING1

Phase mix

PHASE24
PHASE13
PHASE32
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.